Abstract：
UNASSIGNED: Asthma is a common chronic condition in children globally. Allergen-specific immunotherapy, such as subcutaneous (SCIT) and sublingual (SLIT) therapies, are promising by increasing allergen tolerance. This meta-analysis compares the efficacy and safety of SLIT and SCIT in pediatric asthma.
UNASSIGNED: We searched PubMed, Cochrane Library, and Embase for randomized controlled trials and case-control studies comparing SLIT and SCIT in asthmatic children. Meta-analysis was conducted using random-effects models with calculations via R software version 4.3.2 and RevMan version 5.4. Study quality and bias risk were assessed using the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool.
UNASSIGNED: The literature search yielded a total of 1787 records, with 7 studies meeting the inclusion criteria after screening and assessments. There was no significant difference in the Total Asthma Symptoms Score between SLIT and SCIT (mean difference -0.05 [95% CI: -0.21; 0.10]). However, asthma improvement rates were higher in the SLIT group (risk ratio 0.77 [95% CI: 0.64; 0.93]). FEV1 improvement showed no significant difference (mean difference -1.60 [95% CI: -6.27; 3.08]). Adverse events were similar between the treatments (risk ratio 0.56 [95% CI: 0.11; 2.82]).
UNASSIGNED: SLIT and SCIT were generally similarly effective and safe for treating pediatric asthma. SLIT may be preferred due to its noninvasive administration. More research is needed on long-term effects and tailored treatment approaches.
UNASSIGNED: We searched PubMed, Cochrane Library, and Embase for randomized controlled trials and case-control studies comparing SLIT and SCIT in asthmatic children. Meta-analysis was conducted using random-effects models with calculations via R software version 4.3.2 and RevMan version 5.4. Study quality and bias risk were assessed using the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool.
UNASSIGNED: The literature search yielded a total of 1787 records, with 7 studies meeting the inclusion criteria after screening and assessments. There was no significant difference in the Total Asthma Symptoms Score between SLIT and SCIT (mean difference -0.05 [95% CI: -0.21; 0.10]). However, asthma improvement rates were higher in the SLIT group (risk ratio 0.77 [95% CI: 0.64; 0.93]). FEV1 improvement showed no significant difference (mean difference -1.60 [95% CI: -6.27; 3.08]). Adverse events were similar between the treatments (risk ratio 0.56 [95% CI: 0.11; 2.82]).
UNASSIGNED: SLIT and SCIT were generally similarly effective and safe for treating pediatric asthma. SLIT may be preferred due to its noninvasive administration. More research is needed on long-term effects and tailored treatment approaches.
摘要：
■哮喘是全球儿童常见的慢性疾病。过敏原特异性免疫治疗，如皮下（SCIT）和舌下（SLIT）治疗，通过增加过敏原耐受性是有希望的。这项荟萃分析比较了SLIT和SCIT在小儿哮喘中的疗效和安全性。
■我们搜索了PubMed，科克伦图书馆,和Embase用于比较哮喘儿童SLIT和SCIT的随机对照试验和病例对照研究。使用随机效应模型进行Meta分析，并通过R软件4.3.2版和RevMan5.4版进行计算。使用NOS和Cochrane偏差风险工具评估研究质量和偏差风险。
■文献检索共产生1787条记录，筛选和评估后，有7项研究符合纳入标准。SLIT和SCIT之间的总哮喘症状评分（TASS）没有显着差异（平均差异-0.05[95％CI：-0.21;0.10]）。然而,SLIT组哮喘改善率较高(风险比0.77[95%CI:0.64;0.93]).FEV1改善没有显着差异（平均差-1.60[95％CI：-6.27;3.08]）。治疗之间的不良事件相似（风险比0.56[95％CI：0.11;2.82]）。
■SLIT和SCIT对于治疗小儿哮喘通常同样有效和安全。由于其非侵入性施用,SLIT可能是优选的。需要对长期效果和量身定制的治疗方法进行更多研究。
■我们搜索了PubMed，科克伦图书馆,和Embase用于比较哮喘儿童SLIT和SCIT的随机对照试验和病例对照研究。使用随机效应模型进行Meta分析，并通过R软件4.3.2版和RevMan5.4版进行计算。使用NOS和Cochrane偏差风险工具评估研究质量和偏差风险。
■文献检索共产生1787条记录，筛选和评估后，有7项研究符合纳入标准。SLIT和SCIT之间的总哮喘症状评分（TASS）没有显着差异（平均差异-0.05[95％CI：-0.21;0.10]）。然而,SLIT组哮喘改善率较高(风险比0.77[95%CI:0.64;0.93]).FEV1改善没有显着差异（平均差-1.60[95％CI：-6.27;3.08]）。治疗之间的不良事件相似（风险比0.56[95％CI：0.11;2.82]）。
■SLIT和SCIT对于治疗小儿哮喘通常同样有效和安全。由于其非侵入性施用,SLIT可能是优选的。需要对长期效果和量身定制的治疗方法进行更多研究。
